Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arch Therapeutics, Inc. (OTC: ARTH).

Full DD Report for ARTH

You must become a subscriber to view this report.


Recent News from (OTC: ARTH)

Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
FRAMINGHAM, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 8 th LD Micro Invitational. The conference is bein...
Source: GlobeNewswire
Date: May, 15 2018 07:50
Arch Therapeutics Provides Update on Study Initiation and 510(k)
FRAMINGHAM, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it will initiate the previously disclosed study designed to address the Food and Dru...
Source: GlobeNewswire
Date: May, 08 2018 07:50
Arch Therapeutics Provides Update on 510(k)
FRAMINGHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it has utilized the Food and Drug Administration’s (FDA, "the agency") pre-...
Source: GlobeNewswire
Date: March, 12 2018 16:30
OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market presenting companies at the 30 th Annual ROTH Confe...
Source: PR Newswire
Date: March, 08 2018 10:00
Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018
FRAMINGHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 30 th Annual Roth Conference. The conference is ...
Source: GlobeNewswire
Date: March, 05 2018 07:50
Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics' AC5(TM) in a Topical Application
FRAMINGHAM, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Positive data from a clinical study of patients undergoing dermatologic surgery and treated with the AC5™ was published in the peer-reviewed journal Dermatologic Surgery, the official journal of the American Society for Dermatologi...
Source: GlobeNewswire
Date: February, 05 2018 07:50
Arch Therapeutics (ARTH) Presents At 10th Annual Biotech Showcase 2018 - Slideshow
The following slide deck was published by Arch Therapeutics, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: January, 09 2018 13:51
Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase(TM) 2018 Conference on January 8th, 2018
FRAMINGHAM, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at The 10 th Annual Biotech Showcase TM 2018 Conference...
Source: GlobeNewswire
Date: January, 02 2018 07:50
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
FRAMINGHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company has withdrawn its 510(k) notification for its medical device AC5 ...
Source: GlobeNewswire
Date: December, 18 2017 07:50
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017
FRAMINGHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 10 th Annual LD Micro Main Event. The conference ...
Source: GlobeNewswire
Date: November, 28 2017 07:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-07-200.42010.4390.450.4201122,830
2018-07-190.450.4250.4550.42494,800
2018-07-180.430.4350.450.4383,035
2018-07-170.4310.430.43780.425116,892
2018-07-160.43550.43750.4420.43554,078

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-2013,550122,83011.0315Cover
2018-07-19185,300494,80037.4495Short
2018-07-1834,30083,03541.3079Short
2018-07-1730,720116,89226.2807Cover
2018-07-1618,10054,07833.4702Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARTH.


About Arch Therapeutics, Inc. (OTC: ARTH)

Logo for Arch Therapeutics, Inc. (OTC: ARTH)

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding hemostasis , control leaking sealant and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self assembling barrier technology platform with the goal of making care faster and safer for patients. Arch s development stage product candidates include the AC Topical Gel and the AC Surgical Hemostatic Device.

 

 

 

Current Management

  • Terrence W. Norchi / President, CEO
  • Richard E. Davis / CFO
  • Avtar Dhillon / Chairman, Independent Director
    • As former president and CEO of Inovio Pharmaceuticals, Inc. formerly Inovio Biomedical Corporation , Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over million and secured more than million in licensing deals from global companies including Merck and Wyeth now Pfizer . Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.
  • Terrence W. Norchi /
  • James R. Sulat / Independent Director
    • Mr. Sulat also serves as the Chairman of the Board of Directors for Momenta Pharmaceuticals, Inc., a biotech company focused on the analysis, characterization and design of complex pharmaceutical products. Mr. Sulat has served as a member of the Supervisory Board for Valneva SE or its predecessor company, Intercell AG, both European biotech companies focusing on vaccines, since . Mr. Sulat has served as a member of the Board of Directors for AMAG Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of specialty pharmaceutical products, since . Mr. Sulat has served as a member of the Board of Directors for diaDexus, Inc.since . Previously, Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer for Maxygen, Inc., from to , and a member of the Board of Directors for Maxygen, Inc., from to . Mr. Sulat served as CEO, CFO and a member of the Board for Memory Pharmaceuticals Corp., from to . Mr. Sulat previously served in senior executive roles for R.R. Donnelley amp Sons, Co., Chiron Corporation, Stanford Health Services, Inc., and Esprit de Corp, Inc. Mr. Sulat also previously served as a member of the Board of Directors for Codexis, Inc., Ariat International, Inc., General Surgical Innovations, Inc., and Vans, Inc. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.

Current Share Structure

  • Market Cap: $51,607,424 - 03/09/2018
  • Authorized: 300,000,000 - 09/30/2016
  • Issue and Outstanding: 154,052,013 - 01/31/2018

 


Recent Filings from (OTC: ARTH)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: February, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 18 2017
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: November, 15 2017
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: October, 12 2017

 

 


Daily Technical Chart for (OTC: ARTH)

Daily Technical Chart for (OTC: ARTH)


Stay tuned for daily updates and more on (OTC: ARTH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ARTH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARTH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ARTH and does not buy, sell, or trade any shares of ARTH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/